IRIS
CAZZOLA, MARIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.147
AS - Asia 13.937
EU - Europa 10.180
SA - Sud America 1.836
Continente sconosciuto - Info sul continente non disponibili 605
AF - Africa 364
OC - Oceania 39
Totale 45.108
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.681
CN - Cina 6.997
SG - Singapore 2.893
IE - Irlanda 2.214
HK - Hong Kong 1.693
UA - Ucraina 1.569
BR - Brasile 1.359
FI - Finlandia 1.177
DE - Germania 1.135
VN - Vietnam 1.091
RU - Federazione Russa 898
IT - Italia 812
SE - Svezia 753
FR - Francia 682
GB - Regno Unito 495
IN - India 266
CA - Canada 222
BD - Bangladesh 179
AR - Argentina 172
ZA - Sudafrica 134
MX - Messico 123
IQ - Iraq 98
PK - Pakistan 87
JP - Giappone 78
TR - Turchia 77
NL - Olanda 76
CO - Colombia 69
PL - Polonia 63
ID - Indonesia 59
EC - Ecuador 55
VE - Venezuela 54
ES - Italia 53
SA - Arabia Saudita 53
UZ - Uzbekistan 48
AT - Austria 46
MA - Marocco 40
CL - Cile 39
BE - Belgio 36
AU - Australia 33
KE - Kenya 32
PH - Filippine 31
IR - Iran 29
MY - Malesia 27
CZ - Repubblica Ceca 26
JO - Giordania 25
TN - Tunisia 25
EG - Egitto 24
PY - Paraguay 24
BO - Bolivia 22
CR - Costa Rica 21
LT - Lituania 21
AE - Emirati Arabi Uniti 20
EU - Europa 20
IL - Israele 20
JM - Giamaica 20
MU - Mauritius 20
PA - Panama 19
NP - Nepal 18
PE - Perù 18
ET - Etiopia 17
UY - Uruguay 17
AZ - Azerbaigian 16
DZ - Algeria 16
KR - Corea 16
RO - Romania 15
DK - Danimarca 13
LB - Libano 13
NI - Nicaragua 12
PT - Portogallo 12
KZ - Kazakistan 11
SN - Senegal 11
OM - Oman 10
RS - Serbia 10
AL - Albania 9
BG - Bulgaria 9
DO - Repubblica Dominicana 9
PS - Palestinian Territory 9
XK - ???statistics.table.value.countryCode.XK??? 9
CH - Svizzera 8
LV - Lettonia 8
NG - Nigeria 8
BH - Bahrain 7
HN - Honduras 7
KG - Kirghizistan 7
KW - Kuwait 7
MD - Moldavia 7
SK - Slovacchia (Repubblica Slovacca) 7
AM - Armenia 6
GR - Grecia 6
SV - El Salvador 6
SY - Repubblica araba siriana 6
TH - Thailandia 6
A2 - ???statistics.table.value.countryCode.A2??? 5
GD - Grenada 5
GE - Georgia 5
GT - Guatemala 5
QA - Qatar 5
BW - Botswana 4
BY - Bielorussia 4
HU - Ungheria 4
Totale 44.438
Salva come PNG Salva come JPEG
Città #
Chandler 2.219
Dublin 2.210
Jacksonville 1.999
San Jose 1.731
Hong Kong 1.648
Nanjing 1.557
Ashburn 1.450
Singapore 1.429
Dallas 1.230
Beijing 871
Boardman 789
Nanchang 615
Council Bluffs 607
Princeton 516
Lauterbourg 506
Lawrence 494
Wilmington 491
Hebei 462
Shenyang 456
Changsha 412
Los Angeles 400
Ho Chi Minh City 397
Jiaxing 372
Medford 349
New York 263
Helsinki 257
Hangzhou 249
Hanoi 239
Tianjin 238
Buffalo 209
Ann Arbor 206
Milan 167
Santa Clara 164
Redondo Beach 150
Munich 134
Moscow 133
Shanghai 132
Woodbridge 113
São Paulo 108
Norwalk 97
Toronto 95
Orem 89
Johannesburg 82
Seattle 79
Verona 77
Pavia 73
The Dalles 71
Chicago 68
Nuremberg 67
Tokyo 67
Brooklyn 66
Turku 62
Jinan 61
San Francisco 60
Frankfurt am Main 59
Da Nang 58
Haiphong 56
Falls Church 54
Guangzhou 54
Chennai 52
Houston 52
Warsaw 52
Rome 50
Zhengzhou 49
Falkenstein 48
Mexico City 47
Montreal 47
Washington 47
Fairfield 43
Atlanta 42
Tashkent 42
Kunming 41
Baghdad 40
Columbus 40
Stockholm 39
Des Moines 38
London 37
Ningbo 37
Rio de Janeiro 36
Belo Horizonte 35
Brussels 34
Denver 34
Taizhou 31
Boston 29
Hải Dương 29
Manchester 28
Nairobi 28
Phoenix 27
Curitiba 26
Amman 22
Amsterdam 22
Lahore 22
Biên Hòa 21
Brasília 21
Guayaquil 21
Poplar 21
Tappahannock 21
Vienna 21
Buenos Aires 20
Caracas 20
Totale 28.779
Salva come PNG Salva come JPEG
Nome #
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis 191
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. 179
A moderate transfusion regimen may reduce iron loading in beta-thalassemia major without producing excessive expansion of erythropoiesis. 176
A B-cell lymphoproliferative disorder 174
A continuous-time Markov model approach for modeling myelodysplastic syndromes progression from cross-sectional data 174
A model for analysing the cost of autologous peripheral blood progenitor cell (PBPC) transplantation 173
Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation. 169
A modified high-dose dexamethasone regimen for primary systemic amyloidosis 163
Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms 156
A rule-based expert system for automatic implementation of somatic variant clinical interpretation guidelines 153
Familial-skewed X-chromosome inactivation as a predisposing factor for late-onset X-linked sideroblastic anemia in carrier females. 151
ANALYSIS OF THE MITOCHONDRIAL FERRITIN PHYSIOPATHOLOGICAL ROLE IN SIDEROBLASTIC ERYTHROPOIESIS 151
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) 149
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. 147
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndrome 146
Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. 146
A novel germline JAK2 mutation in familial myeloproliferative neoplasms. 146
Blast phase of essential thrombocythemia: A single center study. 145
A prognostic model for predicting the impact of comorbidities on survival of patients with myelodysplastic syndromes 145
A WHO classification-based prognostic scoring system (WPSS) for predicting survival in myelodysplastic syndromes 145
Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia 144
Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2 P95-mutated neoplasms 144
Cord blood-derived hematopoietic progenitor cells: in vitro response to hematopoietic growth factors and their recruitment into the S-phase of the cell cycle. 141
A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron 140
[Pathogenetic mechanisms of chronic myeloid leukemia and the antiproliferative effects of alpha and gamma interferons] 140
A case of persistent eosinophilia 139
Accelerated erythroid repopulation with no stem-cell competition effect in children treated with recombinant human erythropoietin after allogeneic bone marrow transplantation 139
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. 139
Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. 139
Inhibition of c-ABL expression in hematopoietic progenitor cells using antisense oligodeoxynucleotides 137
Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts 137
WALDENSTROM'S HYPERGLOBULINEMIC PURPURA IN HLA IDENTICAL SISTERS. 136
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea 135
Myelodysplastic syndrome with isolated 5q deletion (5q- syndrome). A clonal stem cell disorder characterized by defective ribosome biogenesis. 134
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression 133
Circulating endothelial cell separation from peripheral blood of patients affected by myelodysplastic syndromes: Preliminary results obtained by a new immunomagnetic procedure 132
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders 131
Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes. 131
Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations 131
Mutation Type As a Major Determinant of Clinical Phenotype in Myeloproliferative Neoplasms Associated with Mutant Calreticulin 131
A gain-of-function mutation of JAK2 in myeloproliferative disorders 131
Classification and prognostic evaluation of myelodysplastic syndromes 128
Anemia associata ad endocrinopatie. 127
Cell cycle distribution of cord blood-derived haematopoietic progenitor cells and their recruitment into the S-phase of the cell cycle 126
Microcytic anemia in rheumatoid arthritis. Relationship with activity and duration of the disease and iron status. 125
Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome 124
Abnormal splenic uptake of red cells in long-lasting iron deficiency anemia due to self-induced bleeding (factitious anemia). 123
A chronic lymphoproliferative disorder 123
"In vitro" megakaryocytopoiesis in patients with HIV-related thrombocytopenic purpura. 123
Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms 122
Juvenile chronic myelogenous leukemia: in vitro characterization before and after allogeneic bone marrow transplantation 122
Evidence for a polyclonal nature of the cell infiltrate in sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease). 121
Complex Patterns of Chromosome 11 Aberrations in Myeloid Malignancies Target CBL, MLL, DDB1 and LMO2. 121
MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance 121
Tie2 expressing monocytes in the spleen of patients with primary myelofibrosis 121
An atypical myeloproliferative disorder with high thrombotic risk and slow disease progression. 120
Ittero. 120
Clinical significance of somatic mutation in unexplained blood cytopenia 120
Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms 120
Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis 119
Intracellular calcium deposits and store operated calcium entry in CD34+ cells from patients with myelofibrosis carrying a CALR mutation 119
Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure 119
Clinical severity and thermodynamic effects of iron-responsive element mutations in hereditary hyperferritinemia-cataract syndrome 118
A novel deletion of the L-ferritin iron-responsive element responsible for severe hereditary hyperferritinaemia-cataract syndrome. 117
CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis 116
Tumor necrosis factor alpha down-regulates c-myc mRNA expression and induces in vitro monocytic differentiation in fresh blast cells from patients with acute myeloblastic leukemia. 116
A linkage between hereditary hyperferritinaemia not related to iron overload and autosomal dominant congenital cataract. 115
Cerebrospinal fluid ferritin in human disease. 115
CHARACTERIZATION OF A CELLULAR MODEL FOR THE STUDY OF MITOCHONDRIAL FERRITIN PHYSIOPATHOLOGICAL ROLE IN SIDEROBLASTIC ERYTHROPOIESIS 114
JAK2 (V617F) mutation in healthy individuals 113
The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms 113
Gain of function, loss of control - a molecular basis for chronic myeloproliferative disorders 112
Hereditary hyperferritinemia-cataract syndrome: relationship between phenotypes and specific mutations in the iron-responsive element of ferritin light-chain mRNA. 112
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q 112
Clinical and biological implications of driver mutations in myelodysplastic syndromes 112
A patient-oriented approach to treatment of myelodysplastic syndromes. 112
Revised international prognostic scoring system for myelodysplastic syndromes 112
Hematologic passport for athletes competing in endurance sports: a feasibility study. 111
Advances in understanding the pathogenesis of familial myeloproliferative neoplasms 111
Pan-cancer analysis of whole genomes 111
Basic and acidic isoferritins in the serum of patients with Hodgkin's disease. 110
Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm. 110
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation 110
Allelic imbalance in CALR somatic mutagenesis 109
Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System. 109
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes 108
Classification of anaemia on the basis of ferrokinetic parameters. 108
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms 108
Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. 108
A global strategy for prevention and detection of blood doping with erythropoietin and related drugs 108
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. 108
Relationship between clone metrics and clinical outcome in clonal cytopenia 107
Not just clonal expansion of hematopoietic cells, but also activation of their progeny in the pathogenesis of myeloproliferative disorders 107
USE OF A MONOCLONAL ANTIBODY AGAINST HUMAN HEART FERRITIN FOR EVALUATING ACIDIC FERRITIN CONCENTRATION IN HUMAN SERUM 107
Myelodysplastic syndromes--coping with ineffective hematopoiesis. 107
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia 107
Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders. 107
Effects of granulocyte-macrophage colony-stimulating factor and interleukin-3 on small cell lung cancer cells 107
Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia. 107
Translational pathophysiology: a novel molecular mechanism of human disease 106
Totale 12.807
Salva come PNG Salva come JPEG
Categoria #
all - tutte 198.704
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 198.704
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.156 0 8 65 39 101 130 40 119 120 93 340 1.101
2022/20236.356 743 374 47 520 634 706 3 403 2.629 33 164 100
2023/20242.266 253 446 95 204 219 618 65 137 15 53 60 101
2024/20255.893 156 567 173 188 109 216 239 540 1.230 224 677 1.574
2025/202614.965 1.044 1.234 1.656 1.792 1.504 761 3.040 594 1.224 1.174 573 369
2026/20271.019 332 687 0 0 0 0 0 0 0 0 0 0
Totale 45.108